Fintel reports that on April 8, 2025, HC Wainwright & Co. initiated coverage of VolitionRx (NYSEAM:VNRX) with a Buy ...

H.C. Wainwright argues that Voyager’s presentations at the Alzheimer’s & Parkinson’s Disease meeting April 1-5 “further strengthen the ...

Fintel reports that on April 7, 2025, HC Wainwright & Co. initiated coverage of Fold Holdings (NasdaqCM:FLD) with a Buy ...

Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks.

HC Wainwright initiates Ionis with Buy rating and $45 target, citing strong pipeline, solid revenue, and key clinical ...

Research analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for Mineralys Therapeutics in a report issued on Wednesday, April 2nd. HC Wainwright analyst M. Caufield now ...

HC Wainwright lifted their Q1 2025 EPS estimates for Spectral AI in a note issued to investors on Wednesday, April 2nd. HC ...

H.C. Wainwright analyst Patrick Trucchio initiated coverage of Alto Neuroscience (ANRO) with a Buy rating and $10 price ...

H.C. Wainwright analyst Yi Chen initiated coverage of VolitionRx (VNRX) with a Buy rating and $2.50 price target VolitionRx is a diagnostics ...

Fintel reports that on April 3, 2025, HC Wainwright & Co. initiated coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy recommendation. As of April 2, 2025, the average one-year price target for ...

Fintel reports that on March 7, 2025, HC Wainwright & Co. initiated coverage of Surf Air Mobility (NYSE:SRFM) with a Buy recommendation. As of March 4, 2025, the average one-year price target for ...